Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Hepatocellular Carcinoma | Research article

A stemness-based eleven-gene signature correlates with the clinical outcome of hepatocellular carcinoma

Authors: Liang Hong, Yu Zhou, Xiangbang Xie, Wanrui Wu, Changsheng Shi, Heping Lin, Zhenjing Shi

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Cumulative evidences have been implicated cancer stem cells in the tumor environment of hepatocellular carcinoma (HCC) cells, whereas the biological functions and prognostic significance of stemness related genes (SRGs) in HCC is still unclear.

Methods

Molecular subtypes were identified by cumulative distribution function (CDF) clustering on 207 prognostic SRGs. The overall survival (OS) predictive gene signature was developed, internally and externally validated based on HCC datasets including The Cancer Genome Atlas (TCGA), GEO and ICGC datasets. Hub genes were identified in molecular subtypes by protein-protein interaction (PPI) network analysis, and then enrolled for determination of prognostic genes. Univariate, LASSO and multivariate Cox regression analyses were performed to assess prognostic genes and construct the prognostic gene signature. Time-dependent receiver operating characteristic (ROC) curve, Kaplan-Meier curve and nomogram were used to assess the performance of the gene signature.

Results

We identified four molecular subtypes, among which the C2 subtype showed the highest SRGs expression levels and proportions of immune cells, whereas the worst OS; the C1 subtype showed the lowest SRGs expression levels and was associated with most favorable OS. Next, we identified 11 prognostic genes (CDX2, PON1, ADH4, RBP2, LCAT, GAL, LPA, CYP19A1, GAST, SST and UGT1A8) and then constructed a prognostic 11-gene module and validated its robustness in all three datasets. Moreover, by univariate and multivariate Cox regression, we confirmed the independent prognostic ability of the 11-gene module for patients with HCC. In addition, calibration analysis plots indicated the excellent predictive performance of the prognostic nomogram constructed based on the 11-gene signature.

Conclusions

Findings in the present study shed new light on the role of stemness related genes within HCC, and the established 11-SRG signature can be utilized as a novel prognostic marker for survival prognostication in patients with HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.PubMed Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.PubMed
2.
go back to reference Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.CrossRefPubMedPubMedCentral Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604.CrossRefPubMedPubMedCentral
3.
4.
go back to reference Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.CrossRefPubMed Najafi M, Farhood B, Mortezaee K. Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol. 2019;234(6):8381–95.CrossRefPubMed
5.
go back to reference Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.CrossRefPubMedPubMedCentral Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.CrossRefPubMedPubMedCentral
7.
go back to reference Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.CrossRefPubMedPubMedCentral Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.CrossRefPubMedPubMedCentral
8.
go back to reference Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34(21):2534–40.CrossRefPubMedPubMedCentral Kerr KF, Brown MD, Zhu K, Janes H. Assessing the clinical impact of risk prediction models with decision curves: guidance for correct interpretation and appropriate use. J Clin Oncol. 2016;34(21):2534–40.CrossRefPubMedPubMedCentral
10.
go back to reference Yi L, Huang P, Zou X, Guo L, Gu Y, Wen C, et al. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. Pharmacol Res. 2020;161:105144.CrossRefPubMed Yi L, Huang P, Zou X, Guo L, Gu Y, Wen C, et al. Integrative stemness characteristics associated with prognosis and the immune microenvironment in esophageal cancer. Pharmacol Res. 2020;161:105144.CrossRefPubMed
11.
go back to reference Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338–354.e315.CrossRefPubMedPubMedCentral Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338–354.e315.CrossRefPubMedPubMedCentral
12.
go back to reference Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011;71(5):1772–80.CrossRefPubMed Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, et al. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res. 2011;71(5):1772–80.CrossRefPubMed
13.
go back to reference Müller L, Tunger A, Plesca I, Wehner R, Temme A, Westphal D, et al. Bidirectional crosstalk between Cancer stem cells and immune cell subsets. Front Immunol. 2020;11:140.CrossRefPubMedPubMedCentral Müller L, Tunger A, Plesca I, Wehner R, Temme A, Westphal D, et al. Bidirectional crosstalk between Cancer stem cells and immune cell subsets. Front Immunol. 2020;11:140.CrossRefPubMedPubMedCentral
14.
go back to reference Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17(4):204–32.CrossRefPubMed Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020;17(4):204–32.CrossRefPubMed
15.
go back to reference Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000;119(4):961–71.CrossRefPubMed Silberg DG, Swain GP, Suh ER, Traber PG. Cdx1 and cdx2 expression during intestinal development. Gastroenterology. 2000;119(4):961–71.CrossRefPubMed
16.
go back to reference Mari L, Milano F, Parikh K, Straub D, Everts V, Hoeben KK, et al. A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia. Cell Rep. 2014;7(4):1197–210.CrossRefPubMed Mari L, Milano F, Parikh K, Straub D, Everts V, Hoeben KK, et al. A pSMAD/CDX2 complex is essential for the intestinalization of epithelial metaplasia. Cell Rep. 2014;7(4):1197–210.CrossRefPubMed
17.
go back to reference Zhu R, Wong KF, Lee NP, Lee KF, Luk JM. HNF1α and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem. 2010;111(3):618–26.CrossRefPubMed Zhu R, Wong KF, Lee NP, Lee KF, Luk JM. HNF1α and CDX2 transcriptional factors bind to cadherin-17 (CDH17) gene promoter and modulate its expression in hepatocellular carcinoma. J Cell Biochem. 2010;111(3):618–26.CrossRefPubMed
18.
go back to reference Bernardo AS, Faial T, Gardner L, Niakan KK, Ortmann D, Senner CE, et al. BRACHYURY and CDX2 mediate BMP-induced differentiation of human and mouse pluripotent stem cells into embryonic and extraembryonic lineages. Cell Stem Cell. 2011;9(2):144–55.CrossRefPubMedPubMedCentral Bernardo AS, Faial T, Gardner L, Niakan KK, Ortmann D, Senner CE, et al. BRACHYURY and CDX2 mediate BMP-induced differentiation of human and mouse pluripotent stem cells into embryonic and extraembryonic lineages. Cell Stem Cell. 2011;9(2):144–55.CrossRefPubMedPubMedCentral
19.
go back to reference Wang ZY, Yang J, Liu CK, Shen SQ. High expression of retinoblastoma-binding protein 2 (RBP2) in patients with hepatocellular carcinoma and its prognostic significance. Med Sci Monit. 2017;23:2736–44.CrossRefPubMedPubMedCentral Wang ZY, Yang J, Liu CK, Shen SQ. High expression of retinoblastoma-binding protein 2 (RBP2) in patients with hepatocellular carcinoma and its prognostic significance. Med Sci Monit. 2017;23:2736–44.CrossRefPubMedPubMedCentral
20.
go back to reference Zhou D, Kannappan V, Chen X, Li J, Leng X, Zhang J, et al. RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Exp Mol Med. 2016;48(6):e238.CrossRefPubMedPubMedCentral Zhou D, Kannappan V, Chen X, Li J, Leng X, Zhang J, et al. RBP2 induces stem-like cancer cells by promoting EMT and is a prognostic marker for renal cell carcinoma. Exp Mol Med. 2016;48(6):e238.CrossRefPubMedPubMedCentral
21.
go back to reference Yuan X, Zhou G, Zhai Y, Xie W, Cui Y, Cao J, et al. Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol Biomark Prevent. 2008;17(12):3621–7.CrossRef Yuan X, Zhou G, Zhai Y, Xie W, Cui Y, Cao J, et al. Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma. Cancer Epidemiol Biomark Prevent. 2008;17(12):3621–7.CrossRef
22.
go back to reference Koh WP, Yuan JM, Wang R, Govindarajan S, Oppenheimer R, Zhang ZQ, et al. Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma. Cancer. 2011;117(15):3383–92.CrossRefPubMed Koh WP, Yuan JM, Wang R, Govindarajan S, Oppenheimer R, Zhang ZQ, et al. Aromatase (CYP19) promoter gene polymorphism and risk of nonviral hepatitis-related hepatocellular carcinoma. Cancer. 2011;117(15):3383–92.CrossRefPubMed
23.
go back to reference Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, et al. Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate Cancer cells in the bone marrow. Cancer Res. 2016;76(8):2453–64.CrossRefPubMed Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, et al. Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate Cancer cells in the bone marrow. Cancer Res. 2016;76(8):2453–64.CrossRefPubMed
24.
go back to reference Caplin M, Khan K, Savage K, Rode J, Varro A, Michaeli D, et al. Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J Hepatol. 1999;30(3):519–26.CrossRefPubMed Caplin M, Khan K, Savage K, Rode J, Varro A, Michaeli D, et al. Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma. J Hepatol. 1999;30(3):519–26.CrossRefPubMed
25.
go back to reference Schaer JC, Reubi JC. High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. J Clin Endocrinol Metab. 1999;84(1):233–9.CrossRefPubMed Schaer JC, Reubi JC. High gastrin and cholecystokinin (CCK) gene expression in human neuronal, renal, and myogenic stem cell tumors: comparison with CCK-A and CCK-B receptor contents. J Clin Endocrinol Metab. 1999;84(1):233–9.CrossRefPubMed
26.
go back to reference Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, et al. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med. 2010;16(3–4):102–15.CrossRefPubMed Spano D, Russo R, Di Maso V, Rosso N, Terracciano LM, Roncalli M, et al. Galectin-1 and its involvement in hepatocellular carcinoma aggressiveness. Mol Med. 2010;16(3–4):102–15.CrossRefPubMed
27.
go back to reference Yu Z, Ou Q, Chen F, Bi J, Li W, Ma J, et al. Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. J Transl Med. 2018;16(1):327.CrossRefPubMedPubMedCentral Yu Z, Ou Q, Chen F, Bi J, Li W, Ma J, et al. Evaluation of the prognostic value of paraoxonase 1 in the recurrence and metastasis of hepatocellular carcinoma and establishment of a liver-specific predictive model of survival. J Transl Med. 2018;16(1):327.CrossRefPubMedPubMedCentral
28.
go back to reference Jiang JT, Wu CP, Xu N, Zhang XG. Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma. Hepatobil Pancreatic Dis Int. 2009;8(1):25–8. Jiang JT, Wu CP, Xu N, Zhang XG. Mechanisms and significance of lipoprotein(a) in hepatocellular carcinoma. Hepatobil Pancreatic Dis Int. 2009;8(1):25–8.
29.
go back to reference Wei RR, Zhang MY, Rao HL, Pu HY, Zhang HZ, Wang HY. Identification of ADH4 as a novel and potential prognostic marker in hepatocellular carcinoma. Med Oncol. 2012;29(4):2737–43.CrossRefPubMed Wei RR, Zhang MY, Rao HL, Pu HY, Zhang HZ, Wang HY. Identification of ADH4 as a novel and potential prognostic marker in hepatocellular carcinoma. Med Oncol. 2012;29(4):2737–43.CrossRefPubMed
30.
go back to reference Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13.CrossRefPubMedPubMedCentral Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13.CrossRefPubMedPubMedCentral
31.
go back to reference Lubsen J, Pool J, van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med. 1978;17(2):127–9.CrossRefPubMed Lubsen J, Pool J, van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med. 1978;17(2):127–9.CrossRefPubMed
Metadata
Title
A stemness-based eleven-gene signature correlates with the clinical outcome of hepatocellular carcinoma
Authors
Liang Hong
Yu Zhou
Xiangbang Xie
Wanrui Wu
Changsheng Shi
Heping Lin
Zhenjing Shi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08351-0

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine